Remarkably, the development of HCC was accelerated to ~10 or ~18 weeks post HDT when HA-ARQ62L or HA-ARE81Q were co-injected with NRAS, respectively (Fig. 3b). The gene discussed is NRAS; the disease is hepatocellular carcinoma.